Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Payables (2018 - 2025)

China SXT Pharmaceuticals has reported Payables over the past 8 years, most recently at $1.5 million for Q3 2025.

  • For Q3 2025, Payables rose 30.17% year-over-year to $1.5 million; the TTM value through Sep 2025 reached $1.5 million, up 30.17%, while the annual FY2025 figure was $1.9 million, 4.96% up from the prior year.
  • Payables for Q3 2025 was $1.5 million at China SXT Pharmaceuticals, down from $1.9 million in the prior quarter.
  • Over five years, Payables peaked at $3.5 million in Q1 2022 and troughed at $1.2 million in Q3 2024.
  • A 5-year average of $1.9 million and a median of $1.6 million in 2022 define the central range for Payables.
  • Biggest five-year swings in Payables: skyrocketed 35.2% in 2021 and later tumbled 56.22% in 2023.
  • Year by year, Payables stood at $1.5 million in 2021, then increased by 2.43% to $1.6 million in 2022, then grew by 1.91% to $1.6 million in 2023, then dropped by 26.87% to $1.2 million in 2024, then skyrocketed by 30.17% to $1.5 million in 2025.
  • Business Quant data shows Payables for SXTC at $1.5 million in Q3 2025, $1.9 million in Q1 2025, and $1.2 million in Q3 2024.